Why the study?
Knowledge gaps and challenges remained in fully understanding the role of Lp(a) in CVD and CAVD, despite evidence that it is a causal mediator.
Design
Working group recommendations
Answers are grounded in this paper and cite their sources.
This NHLBI working group report outlines critical knowledge gaps and provides recommendations to advance research on Lipoprotein(a) as a causal mediator of cardiovascular disease and calcific aortic valve disease.
Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). Specific therapies to address Lp(a)-mediated CVD and CAVD are in clinical development. Due to knowledge gaps, the National Heart, Lung, and Blood Institute organized a working group that identified challenges in fully understanding the role of Lp(a) in CVD/CAVD. These included the lack of research funding, inadequate experimental models, lack of globally standardized Lp(a) assays, and inadequate understanding of the mechanisms underlying current drug therapies on Lp(a) levels. Specific recommendations were provided to facilitate basic, mechanistic, preclinical, and clinical research on Lp(a); foster collaborative research and resource sharing; leverage expertise of different groups and centers with complementary skills; and use existing National Heart, Lung, and Blood Institute resources. Concerted efforts to understand Lp(a) pathophysiology, together with diagnostic and therapeutic advances, are required to reduce Lp(a)-mediated risk of CVD and CAVD.
No takes yet. Share an insight, caveat, or question.
Tsimikas et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: